Lincomycin

Template:Infobox drug/title

Clinical data
Trade names	Biocine, Lincocin
AHFS/Drugs.com	Monograph
MedlinePlus	a609005
License data	Template:Infobox drug/licence
Routes of administration	IM/IV
ATC code	J01FF02 (WHO) QJ51FF02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)Template:Infobox drug/non-ref-space US: ℞-onlyTemplate:Infobox drug/non-ref-space
Pharmacokinetic data
Bioavailability	N/A
Elimination half-life	5.4 ± 1.0 h after IM or IV administration
Excretion	Kidney and bile duct
Identifiers
IUPAC name (2S,4R)-N-[(1R,2R)-2-Hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
CAS Number	Template:Infobox drug/formatCASnumber Template:Infobox drug/formatCASnumber
PubChem CID	Template:Infobox drug/formatPubChemCID Template:Infobox drug/formatPubChemCID
PubChem SID	Template:Infobox drug/formatPubChemSID Template:Infobox drug/formatPubChemSID
IUPHAR/BPS	Template:Infobox drug/formatIUPHARBPS Template:Infobox drug/formatIUPHARBPS
DrugBank	Template:Infobox drug/formatDrugBank Template:Infobox drug/formatDrugBank
ChemSpider	Template:Infobox drug/formatChemSpider Template:Infobox drug/formatChemSpider
UNII	Template:Infobox drug/formatUNII Template:Infobox drug/formatUNII
KEGG	Template:Infobox drug/formatKEGG Template:Infobox drug/formatKEGG
ChEBI	Template:Infobox drug/formatChEBI Template:Infobox drug/formatChEBI
ChEMBL	Template:Infobox drug/formatChEMBL Template:Infobox drug/formatChEMBL
NIAID ChemDB	Template:Infobox drug/formatChemDBNIAID Template:Infobox drug/formatChemDBNIAID
PDB ligand	Template:Infobox drug/formatPDBligand Template:Infobox drug/formatPDBligand
E number	{{#property:P628}}
CompTox Dashboard (EPA)	Template:Infobox drug/formatCompTox Template:Infobox drug/formatCompTox
ECHA InfoCard	{{#property:P2566}}Template:EditAtWikidata
Chemical and physical data
Formula	Template:Infobox drug/chemical formula
Molar mass	406.54 g·mol−1
3D model (JSmol)	Template:Infobox drug/formatJmol Template:Infobox drug/formatJmol
SMILES O=C(N[C@@H]([C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O)[C@H](O)C)[C@H]2N(C)C[C@H](CCC)C2
InChI InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1 Y Key:OJMMVQQUTAEWLP-KIDUDLJLSA-N Y
Data page
Template:Infobox drug/data page link
NY (what is this?)  (verify)

Lincomycin is a lincosamide antibiotic that comes from the actinomycete Streptomyces lincolnensis. A related compound, clindamycin, is derived from lincomycin by using thionyl chloride to replace the 7-hydroxy group with a chlorine atom with inversion of chirality. It was released for medical use in September 1964.

Uses

Although similar in antibacterial spectrum and mechanism of action to macrolides, lincomycin is also effective against other organisms including actinomycetes and some species of Mycoplasma and Plasmodium.

However, because of its adverse effects and toxicity, it is rarely used today and reserved for patients allergic to penicillin or where bacteria have developed resistance.

Clinical pharmacology

Intramuscular administration of a single dose of 600 mg of Lincomycin produces average peak serum levels of 11.6 μg/mL at 60 min, and maintains therapeutic levels for 17 h to 20 h, for most susceptible gram-positive organisms. Urinary excretion after this dose ranges from 1.8% to 24.8% (mean: 17.3%).

A two-hour intravenous infusion of 600 mg of Lincomycin achieves average peak serum levels of 15.9 μg/mL and yields therapeutic levels for 14 h for most susceptible gram-positive organisms. Urinary excretion ranges from 4.9% to 30.3% (mean: 13.8%).

The biological half-life after IM or IV administration is 5.4 ± 1.0 h. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function, compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing lincomycin from the serum.

Tissue level studies indicate that bile is an important route of excretion. Significant levels have been demonstrated in the majority of body tissues. Although lincomycin appears to diffuse in the cerebrospinal fluid (CSF), levels of lincomycin in the CSF appear inadequate for the treatment of meningitis.

Biosynthesis

Lincomycin is an antibiotic classified as a member of the lincosamide class, which typically features a L-proline amino acid derivative linked through amide group with an eight-carbon aminothio sugar. The two units 4-propyl-L-proline and the amino-octose, are each synthesized separately, and are then condensed by LmbD protein, and then further postcondensation reactions involving cleaving of mycothiol, deacetylation, and S-methylation finally yield lincomycin.

The biosynthesis of the amino acid moiety of lincomycin, starts with tyrosine which is transformed to 4-propyl-L-proline by the consecutive action of LmbB1, LmbB2, LmbW, LmbA and LmbX proteins. 4-Propyl-L-proline is activated by LmbC and loaded into LmbN, a bifunctional peptidyl carrier protein, and is ready for condensation by LmbD.

The biosynthetic pathway for production of the amino-octose moiety is almost fully elucidated although the order of the steps still needs further research. Condensation through a transaldolase (LmbR) of ribose 5-phosphate (C5) with fructose 6-phosphate or sedoheptulose-7-phosphate (providing a C3 unit) forms the octose (C8). Further transformations involving isomerization (LmbN), 1-phosphorylation (LmbP), 8-dephosphorylation (LmbK), guanosine diphosphate attachment at position 1 (LmbO), 4-epimerization (LmbM), 6-oxidation (LmbL), amination (LmbS), imine reduction (LmbZ) and 8-reduction, are performed to construct the amino-octose unit. LmbT protein exchange GDP by ergothioneine and the condensation with 4-propyl-L-proline and catalysed by LmbD can occur. The amide-linked product between the amino acid and the amino-octose bound to ergothioneine is then the substrate of LmbV, which substitute ergothioneine by mycothiol. The mycothiol moiety is then cleaved by LmbE, and the product is further processed by LmbIH, LmbQ, LmbJ, LmbF and is finally sulphur methylated by LmbG, to afford lincomycin.

Spectrum of susceptibility

Lincomycin is a narrow spectrum antibiotic with activity against Gram-positive and cell wall-less bacteria including pathogenic species of Streptococcus, Staphylococcus, and Mycoplasma. Lincomycin is used to treat severe bacterial infections in patients who cannot use penicillin antibiotics. Lincomycin shows weak activity against most Gram-negative bacteria. The following represents susceptibility (MIC) data for a few pathogenic bacteria:

• Staphylococcus aureus - 0.2 μg/mL - 32 μg/mL
• Streptococcus pneumoniae - 0.05 μg/mL - 0.4 μg/mL
• Streptococcus pyogenes - 0.04 μg/mL - 0.8 μg/mL